A delegation of biotech investors met with a congressional commission charged with safeguarding U.S. biotech competitiveness, urging policies that respond to China’s rapid gains in clinical trials and drug development. At a related House hearing, a BIO board member and industry CEO testified that Chinese reforms — including an implied‑approval IND process and faster site activation — have cut timelines and attracted licensing deals, shifting where global clinical data is generated. Witnesses argued for policy responses to preserve U.S. innovation leadership, citing industry metrics that show rising Chinese participation in high‑value transactions and the strategic implications for manufacturing, IP and national security.